Sinclair Dunlop - Sep 23, 2024 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Director
Signature
/s/ David Watson, attorney-in-fact for Sinclair Dunlop
Stock symbol
APLS
Transactions as of
Sep 23, 2024
Transactions value $
$60,674
Form type
4
Date filed
9/24/2024, 04:20 PM
Previous filing
Sep 17, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $60.7K +4.6K +3.12% $13.19 152K Sep 23, 2024 Direct
holding APLS Common Stock 100K Sep 23, 2024 Indirect Owner (Epidarex) F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -4.6K -100% $0.00 0 Sep 23, 2024 Common Stock 4.6K $13.19 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities are held by Epidarex and the reporting person, a general partner of Epidarex, may be deemed to have voting and dispositive power over the shares held by Epidarex. The reporting person disclaims beneficial ownership over the shares held by Epidarex except to the extent of his pecuniary interest therein.
F2 This option was granted on January 1, 2019 and fully vested.